Brukinsa Gains Approval for Chronic Lymphocytic Leukemia
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
Researchers sought to determine whether uMRD could determine discontinuation of venetoclax or the addition of ibrutinib in patients with R/R CLL.
Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
The incidence of cutaneous adverse events in cancer patients receiving PI3K inhibitors may be as high as 29%, a meta-analysis suggests.
Zanubrutinib can improve progression-free survival, when compared with bendamustine-rituximab, in previously untreated CLL/SLL, a phase 3 trial suggests.
Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.
Researchers sought to determine whether there was a link between TAp63 and disease aggressiveness in patients with CLL.
Researchers sought to determine whether liso-cel would have acceptable toxicity and effectiveness in patients with SLL or CLL.
Of the NHL patients with neutralizing antibodies against the WA1/2020 SARS-CoV-2 strain, 70% had antibodies against the delta variant, and 33% had antibodies against the omicron variant.